Mechanistic target of rapamycin complex 1 downstream effectors (mTORC1 effectors)

mTORC1 downstream effectors are a collection of proteins that execute the biological commands of the Mechanistic Target of Rapamycin Complex 1 (mTORC1) to regulate cell growth and metabolism (Saxton & Sabatini, 2017, Cell). The most well-characterized effectors are p70S6 Kinase 1 (S6K1) and Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which promote protein synthesis by enhancing mRNA translation (Ben-Sahra & Manning, 2017, FEBS J). Additionally, mTORC1 phosphorylates ULK1 to inhibit autophagy and TFEB to suppress lysosomal biogenesis, thereby coordinating anabolic and catabolic pathways based on nutrient availability (Laplante & Sabatini, 2012, Cell). In many cancers and metabolic disorders, these effectors are constitutively active, driving pathological cell proliferation and resistance to apoptosis (Liu & Sabatini, 2020, Nature Reviews Molecular Cell Biology). Therapeutic strategies primarily utilize mTOR inhibitors, such as Rapamycin and its analogs (Everolimus, Temsirolimus), which block the phosphorylation of these effectors to arrest the cell cycle and induce autophagy (Benjamin et al., 2011, Nature Reviews Drug Discovery). Emerging research also focuses on direct inhibitors of specific effectors, such as S6K1, to achieve more targeted therapeutic outcomes with potentially fewer side effects.

Other names

mTORC1 substratesmTORC1 signaling componentsmTORC1 downstream targetsmTORC1 signaling pathway

Drugs typically inhibit the upstream kinase mTORC1, which prevents the phosphorylation of these downstream effectors. This inhibition leads to decreased protein synthesis (via 4E-BP1 and S6K1) and increased autophagy (via ULK1) (Saxton & Sabatini, 2017, Cell).